BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37821306)

  • 1. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
    Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
    Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
    Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
    Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
    Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
    Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
    Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (
    Bou Zerdan M; Ashok Kumar P; Haroun E; Srivastava N; Ross J; Sivapiragasam A
    Oncotarget; 2023 Mar; 14():178-187. PubMed ID: 36913304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study.
    Necchi A; Spiess PE; Bandini M; Basile G; Grivas P; Bratslavsky G; Jacob J; Danziger N; Lin D; Decker B; Sokol ES; Huang RSP; Kulkarni SB; Ross JS
    Oncologist; 2022 Dec; 27(12):1016-1024. PubMed ID: 35881043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.
    Basin MF; Bratslavsky G; Nahhas N; Basnet A; Goldberg H; Necchi A; Sokol ES; Ramkissoon SH; Huang RSP; Ross JS; Jacob JM
    Urol Oncol; 2023 Feb; 41(2):109.e15-109.e22. PubMed ID: 36443178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
    Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
    Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
    Xing D; Fadare O
    Semin Diagn Pathol; 2021 Jan; 38(1):50-61. PubMed ID: 33032902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
    Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
    Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
    Leary JB; Enright T; Bakaloudi DR; Basnet A; Bratslavsky G; Jacob J; Spiess PE; Li R; Necchi A; Kamat AM; Pavlick DC; Danziger N; Huang RSP; Lin DI; Cheng L; Ross J; Talukder R; Grivas P
    Target Oncol; 2024 May; 19(3):447-458. PubMed ID: 38570422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
    Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
    Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.
    Kim R; Hong JY; Lee J; Kwon GY; Jeong BC; Park SH
    Cancer Res Treat; 2022 Jul; 54(3):894-906. PubMed ID: 34793662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic characterization of vulvar squamous cell carcinoma reveals differential gene expression based on clinical outcome.
    Gordinier ME; Schau GF; Pollock SB; Shields LBE; Talwalkar S
    Gynecol Oncol; 2024 Jan; 180():111-117. PubMed ID: 38086165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
    Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
    Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
    Qin Y; Luan J; Zhou X; Li Y
    Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.